JIBTVA  Vol.3 No.2 , April 2014
Additional Treatment Modality to Improve Outcomes in Myocardial Infarctions and Strokes
In 1974, in Nature, we hypothesized that removal of cytokines can be effective in the treatment of certain inflammatory diseases, e.g., rheumatoid arthritis (RA). We call this approach anticytokino-therapy. Later it was shown that neutralization of pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interferon alpha (IFN-α), interferon gamma (IFN-γ), and interleukin 6 (IL-6), leads to a good therapeutic effect. Anticytokinotherapy is currently used around the world for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, and other Th-1-mediated inflammatory diseases. Pro-inflammatory cytokines have also been found in other conditions (myocardial infarctions, strokes, chronic pain syndromes, etc.). This leads us to believe that hyper- production of pro-inflammatory cytokines forms a basis of a variety of pathological conditions and represents a uniform response of the organism to a wide variety of insults in any part of the body. Thus, we propose to add monoclonal antibodies to (or other blockers of) pro-inflammatory cytokines to the treatment regimens for myocardial infarctions, strokes, and possibly other Th-1-mediated diseases.

Cite this paper
Skurkovich, S. and Skurkovich, B. (2014) Additional Treatment Modality to Improve Outcomes in Myocardial Infarctions and Strokes. Journal of Immune Based Therapies, Vaccines and Antimicrobials, 3, 29-31. doi: 10.4236/jibtva.2014.32004.
[1]   Skurkovich, S.V., Klinova, E.G., Aleksandrovskaya, I.M., Levina, N.V., Arkhipova, N.A. and Bulicheva, T.I. (1973) Stimulation of Transplantation Immunity and Plasma Cell Reaction by Interferon in Mice. Immunology, 25, 317-322.

[2]   Skurkovich, S.V., Klinova, E.G., Eremkina, E.I. and Levina, N.V. (1974) Immunosuppressive Effect of an Anti-Interferon Serum. Nature, 247, 551-552.

[3]   Skurkovich, S. and Skurkovich, B. (1989) The Development of Autoimmune Diseases is Connected with the Initial Disturbance of Interferon Synthesis in the Cells. Journal of Interferon Research, 9, S305.

[4]   Skurkovich, S.V., Loukina, G.V., Sigidin, Y.A. and Skurkovich, B. (1998) Successful First-Time Use of Antibodies to Interferon-Gamma Alone and Combined with Antibodies to Tumor Necrosis Factor Alpha to Treat Rheumatic Diseases (Rheumatoid Arthritis, Systemic Lupus Erythemotosus, Psoriatic Arthritis, Behcet’s Syndrome). Intern Journal of Immunotherapy, 14, 23-32.

[5]   Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., Breedveld, F.C., Macfarlane, J.D., Bijl, H. and Woody, J.N. (1994) Randomized Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumor Necrosis Factor Alpha (cA2) versus Placebo in Rheumatoid Arthritis. Lancet, 344, 1105-1110.

[6]   Skurkovich, B. and Skurkovich, S. (2006) Inhibition of IFN-as a Method of Treatment of Various Autoimmune Diseases, Including Skin Diseases. Ernst Schering Res Found Workshop, 56, 1-27. http://dx.doi.org/10.1007/3-540-37673-9_1

[7]   Sharma, H.S. and Das, D.K. (1997) Role of Cytokines in Myocardial Ischemia and Reperfusion. Mediators Inflammation, 6, 175-183.

[8]   Starke, R.M., Raper, D.M., Ding, D., Chalouhi, N., Owens, G.K., Hasan, D.M., Mendel, R. and Dumont, A.S. (2013) Tumor Necrosis Factor-Modulates Cerebral Aneurism Formation and Rupture. Translational Stroke Research, 5, 269- 277.

[9]   Simms, R.W. and Korn, J.H. (2002) Cytokine Directed Therapy in Scleroderma: Rationale, Current Status, and the Future. Current Opinion in Rheumatology, 14, 717-722.

[10]   Canady, J., Karrer, S., Fleck, M. and Bosserhoff, A.K. (2013) Fibrosing Connective Tissue Disorders of the Skin: Molecular Similarities and Distinctions. Journal of Dermatological Science, 70, 151-158.